Evidence map›Paper›PMID 17068145›Full record

ArticleBlood2007

Differential epitope mapping of antibodies to PDC-E2 in patients with hematologic malignancies after allogeneic hematopoietic stem cell transplantation and primary biliary cirrhosis.

Roberto Bellucci, Sabine Oertelt, Meagan Gallagher, Sigui Li, Emmanuel Zorn, Edie Weller, Fabrice Porcheray, Edwin P Alyea, Robert J Soiffer, Nikhil C Munshi and 2 more

Open access · greenAbstract read
In one paragraph

Article in Blood, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.5field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Graft-versus-leukemia antigen CML66 elicits coordinated B-cell and T-cell immunity after donor lymphocyte infusion.Clinical cancer research : an official journal of the American Association for Cancer Research · 2010
    Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Roberto BellucciDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
Sabine Oertelt
Meagan Gallagher
Sigui Li
Emmanuel Zorn
Edie Weller
Fabrice Porcheray
Edwin P Alyea
Robert J Soiffer
Nikhil C Munshi
M Eric Gershwin
Jerome Ritz
Dana-Farber Cancer Institute · USUniversity of California, Davis · USHarvard University · USWoman's Hospital · US

Funding

Targeting Myeloma Cell-Host Bone Marrow InteractionsP01CA078378 · NCI · DANA-FARBER CANCER INSTITUTE · PI ANDERSON, KENNETH C. · 1998 to 2014
$26.2M
Reconstitution of Regulatory T Cells after Allogeneic Stem Cell TransplantationU19AI029530 · NIAID · DANA-FARBER CANCER INSTITUTE · PI SOIFFER, ROBERT JON · 2005 to 2010
$9.0M
T CELL NEOGENESIS AFTER STEM CELL TRANSPLANTATIONP01AI029530 · NIAID · DANA-FARBER CANCER INSTITUTE · PI RITZ, JEROME · 1990 to 2003
$4.5M
MECHANISMS AND PATHOGENESIS OF PRIMARY BILIARY CIRRHOSISR37DK039588 · NIDDK · UNIVERSITY OF CALIFORNIA DAVIS · PI GERSHWIN, MERRILL E · 2001 to 2010
$3.5M
Immune Deregulation and Chronic Humoral Rejection of Kidney Allografts in HumansR01DK083352 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI ZORN, EMMANUEL · 2010 to 2014
$2.1M
MECHANISMS AND PATHOGENESIS OF PRIMARY BILIARY CIRRHOSISR01DK039588 · NIDDK · UNIVERSITY OF CALIFORNIA DAVIS · PI GERSHWIN, MERRILL E · 1988 to 2015
$2.0M
NCI NIH HHS CA078378NCI NIH HHS P01 CA078378NIAID NIH HHS AI29530NIAID NIH HHS P01 AI029530NIAID NIH HHS U19 AI029530NIDDK NIH HHS DK037003NIDDK NIH HHS DK39588NIDDK NIH HHS R01 DK039588NIDDK NIH HHS R01 DK083352NIDDK NIH HHS R37 DK039588
6 · The paper itself

Abstract

A unique characteristic of the autoimmune liver disease primary biliary cirrhosis (PBC) is the presence of high-titer and extremely specific autoantibodies to the E2 component of the pyruvate dehydrogenase complex (PDC-E2). Autoantibodies to PDC-E2 antigen have only been detected in patients with disease or in those who subsequently develop PBC. One exception has been a subgroup of patients with multiple myeloma (MM) who underwent allogeneic hematopoietic stem cell transplantation (HSCT) and received donor lymphocyte infusions (DLIs) after transplantation. These patients developed high-titer antibodies to a variety of myeloma-associated antigens, including PDC-E2, coincident with rejection of myeloma cells in vivo. To examine the specificity of autoantibodies to PDC in these patients, we screened sera from patients with MM, chronic leukemias, monoclonal gammopathy of unknown significance (MGUS), PBC, and healthy donors. Three of 11 patients with MM (27%) and 2 of 6 patients with chronic leukemias (33%) developed anti-PDC-E2 antibodies in association with DLI response; 2 of 12 (17%) patients in the MGUS pretreatment control population also had detectable anti-PDC responses. Interestingly, the epitope specificity of these PDC-E2 autoantibodies was distinctive, suggesting that the mechanisms leading to loss of tolerance in the transplantation patients are distinct from PBC.

Indexed as

AgedAntibodiesCell Line, TumorDihydrolipoyllysine-Residue AcetyltransferaseEpitope MappingFemaleHealthHematopoietic Stem Cell TransplantationHumansLiver Cirrhosis, BiliaryMaleMiddle AgedMitochondrial ProteinsParaproteinemiasTransplantation, HomologousAntibodiesDihydrolipoyllysine-Residue AcetyltransferaseMitochondrial Proteins

Identifiers

PMID17068145
PMCPMC1801041
OpenAlexW1978418201

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.